MBXBF News Alert Microbix Biosystems (MBXBF) 0.5170 09/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Microbix Biosystems (MBXBF) 0.5170 $MBXBF

IIROC Trade Resumption - Microbix Biosystems Inc.
Newsfile Corp - Fri Aug 22, 12:57PM CDT
Trading resumes in:

IIROC Trade Halt - Microbix Biosystems Inc.
Newsfile Corp - Fri Aug 22, 12:17PM CDT
The following issues have been halted by IIROC:

eResearch Posts Update Report on Microbix Biosystems Inc.
ACCESSWIRE - Wed Feb 26, 1:52PM CST
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.

eResearch Posts Perspective on Microbix Biosystems Inc.
ACCESSWIRE - Mon Jan 27, 6:27AM CST
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.

IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - Microbix Biosystems Inc., MBX
Marketwire Canada - Thu Jan 23, 11:49AM CST
Trading resumes in / Reprise des negociations pour :

Competitor Analysis: Thrombolytics & Fibrinolytics
M2 - Mon May 20, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j3c6qc/competitor) has announced the addition of the "Competitor Analysis: Thrombolytics & Fibrinolytics" report to their offering. The Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report provides information on the various generation of marketed thrombolytics and includes a compilation of current active projects in research and development of novel thrombolytics and fibrinolytics including those in development in ophthalmology and in less regulated markets. In addition, the report lists company-specific product portfolios and R&D pipelines of thrombolytics and fibrinolytics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Examples of Companies Mentioned - Actavis - Alcon - Astellas Pharma - Bharat Biotech - Biocon - BioGeneric Pharma - Cadila Pharma - Cerbios Pharma - Cerevast Therapeutics - CSL Behring - Dexa Medica - Eisai - Ekos Corp - Grifols - Heber Biotec - Kedrion - Kee Pharma - Lundbeck - Microbix Biosystems - Mitsubishi Tanabe Pharma - Nanogen Biopharmaceuticals - ProteomTech - Pulse Therapeutics - Roche (Genentech) - Shantha Biotechnics (Sanofi) - Techpool BioPharma - Thrombogenics - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/j3c6qc/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Microbix reports fiscal 2013 first quarter results
CNW Group - Thu Feb 14, 6:30AM CST
Company Provides Update on Product Pipeline

Microbix Sells Purified Water Business
CNW Group - Fri Feb 01, 6:30AM CST
Microbix Biosystems Inc. (TSX: MBX), a biotechnology company developing innovative biological products and technologies, today announced it has sold its Water-for-Injection business to Irvine Scientific in California. The sale was constructed on an earn-out basis, though specific deal terms were not disclosed.

Microbix' LumiSort Patent Upheld in U.S.
CNW Group - Fri Jan 25, 6:25AM CST
Sexing Technologies fails in second attempt to invalidate claims

Microbix Refiles Financial Statements
CNW Group - Thu Jan 10, 4:41PM CST
Microbix Biosystems Inc. (TSX:MBX) today refiled its financial statements for the year ended September 30, 2012 to correct two oversights in the Consolidated Statements of Comprehensive Loss.

Microbix Reports 15% Increase In Virology Product Sales In 2012
CNW Group - Fri Dec 28, 10:33PM CST
Urokinase, Vaccine Venture, and LumiSort Update




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading

Top 5 Most Recently Viewed Articles

Celcuity Inc. Prepares for Third Quarter Financial Results

Updated Category News Views 91

Celcuity Inc. Announces Upcoming Financial Results Release Celcuity Inc. (NASDAQ: CELC), a pioneering biotechnology company focused on innovative oncology therapies, has exciting news. The company will be releasing its financial results for the third quarter of 2025 after the market closes. This significant event is scheduled for a Wednesday, with management set to...

Continue Reading
EverTrue and DonorSearch Team Up to Revolutionize Fundraising

Updated Category News Views 973

EverTrue's Strategic Acquisition of DonorSearch EverTrue, a leader in donor engagement and pipeline development, recently announced a significant acquisition. The company has acquired DonorSearch, known for its innovative AI-powered donor discovery solutions. This strategic move is aimed at enhancing the capabilities of fundraising teams, enabling them to connect with...

Continue Reading
Celebrating Creativity and Inclusion: ADCOLOR Awards 2025

Updated Category News Views 315

ADCOLOR Awards 2025: A Night of Inspiration and Celebration Presented by leading organizations in the industry like Amazon, Disney, and Meta, the ADCOLOR Awards is a prestigious event celebrating remarkable individuals and organizations that champion diversity and inclusion in creative fields. This year's ceremony showcased inspiring figures such as Richelieu Dennis,...

Continue Reading
Transforming a $1000 Investment in First Solar to $3700

Updated Category News Views 161

Transform Your Investment with First Solar First Solar (NASDAQ: FSLR) has shown impressive performance over the past decade. This company has not only managed to keep pace with the market but has actually outperformed it by an average of 2.49% annually. This impressive annualized return translates to an average annual growth of 14.22%, making First Solar a notable player...

Continue Reading
Carpenter Technology Announces New Quarterly Dividend Plans

Updated Category News Views 107

Carpenter Technology Announces Quarterly Cash Dividend Carpenter Technology Corporation (NYSE: CRS), a leading name in high-performance specialty alloys, has made a significant announcement regarding its quarterly cash dividend. The company's Board of Directors has declared a dividend of $0.20 per share on common stock, underscoring its commitment to returning value to...

Continue Reading